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The communicative enthusiasm of Lloyd Old
Before starting this introduction on the development of 
monoclonal antibodies for cancer therapy and the role of Lloyd 
Old in the field, in parallel with his central interest in T cell 
activation by tumor antigen vaccination, let me say a few 
subjective words about a unique human quality of Lloyd: his 
extraordinary communicative enthusiasm. That quality is 
sometimes called charisma, but there is more to it than that; it is 
a capacity to communicate your interest to your fellow scientists 
(in the sense of “love your neighbor” in the scriptures) and to 
give to your interlocutor the impression of being fully 
understood. The result was that, when you came out of Lloyd’s 
office after a scientific dialogue, you felt “boosted” to develop 
your project with renewed energy and more imagination.
Lloyd had this kind of positive influence on so many fields and 
so many personalities that it is not possible to mention them all. 
I will first mention, very briefly, the two most representative 
well-known examples by which Lloyd stimulated and 
contributed to the field of cancer immunotherapy, and then 
follow with several other examples in the field of monoclonal 
antibodies by mentioning the central personalities who worked 
with him or independently, including myself and a few co-
workers from my group who enjoyed the privilege of having 
interacted with him. While writing this kind of personal review, 
I kept in mind this question: would Lloyd enjoy reading it and 
would he agree with the points I am trying to underscore?
The first example in the field of immunotherapy was the 
discovery of the MAGE genes as the source of antigens 
recognized by tumor-reactive T cells, which was initiated and 
developed by Thierry Boon’s group in the Brussels Branch of the 
Ludwig Institute for Cancer Research (LICR) (1, 2). Lloyd 
himself had pursued passionately the identification of T cell-
defined tumor antigens. Together with one of his fellows, 
Alexander Knuth, they systematically analyzed the tumor-
reactive CD8 T cells, which could be expanded in autologous 
mixed lymphocyte-tumor cell culture (3). It was subsequently a 
collaboration of Knuth with Boon that allowed the discovery of 
MAGE-A1 (1). Furthermore, Lloyd, along with Yao-Tseng 
Chen, had a central role in the field by the discovery of NY-ESO-
1 antigen (4) and its broad extension by the definition of the 
concept of Cancer/Testis (CT) antigens (5).
The second major example is the SEREX method, using a 
bacterial expression library for detecting patients’ serum 
antibodies reacting with tumor antigens (6). This methodology 
was described independently by Lloyd’s former collaborator, 
Michael Pfreundschuh, but Lloyd had already for many years a 
major interest in the use of patient serum for autologous typing 
and immensely broadened the application of the SEREX 
method, up to the description of the immunome (7) and the 
SEREX database, in collaboration with the late Matthew 
Scanlan. The antibodies discovered by this technology were not 
used for therapy, but they represented precious evidence of 
patients’ immune responses against their own tumors, and, most 
importantly, SEREX-detected antibodies led to the 
identification of several new Cancer/Testis antigens, including 
the most important, NY-ESO-1. In addition to these two 
emblematic examples, we can say, without risk of contradiction, 
that since he took over the direction of the LICR in 1988, Lloyd 
spread his enthusiastic and liberal spirit within all the different 
branches of LICR.
Radiolabeled antibodies
My initial contacts with Lloyd were through work in the field 
of radiolabeled antibodies. As early as 1974, in collaboration 
with Stefan Carrel, we had shown in a nude mouse/human colon 
carcinoma xenograft model that I-labeled, 
immunoabsorbent-purified, high-affinity polyclonal antibodies 
against carcinoembryonic antigen (CEA) could specifically 
localize in significant amounts in tumors (8). The subsequent 
clinical studies, performed by David Goldenberg’s group (9) and 
ourselves (10), both with 131I-labeled anti-CEA polyclonal 
antibodies, gave precise evidence of specific tumor localization, 
but we considered the usefulness of tumor detection by the so-
called immunoscintigraphy more cautiously than our 
competitor.
Soon after the discovery of the monoclonal antibody 
technology by César Milstein and Georges Köhler, we produced, 
with Roberto Accolla, the first anti-CEA monoclonal antibodies 
(mAbs) (11), and in 1981, we reported the first clinical trial of 
radiolabeled mAb injection (12). Twenty-eight patients with 
CEA-producing carcinomas were injected with 131I-labeled 
anti-CEA mAb and tested by external photoscanning and 
tomoscintigraphy (SPECT). The tumor-specific localization of 
radiolabeled mAb was confirmed, but the absolute amounts of 
radioactivity delivered to the tumor were low. This initial 
clinical trial was followed by several more with second 
generation anti-CEA mAbs and fragments labeled with 123I 
(13), by 111In (14), and later, using a chimeric anti-CEA mAb 
labeled with different fluorescent molecules, allowing the direct 
tumor visualization and opening the field of immuno-
photodetection (15, 16).
Interestingly, it was at the time of the first clinical evaluation of 
radiolabeled anti-CEA mAb that Richard Miller and Ron Levy 
reported the first treatment of patients with cutaneous T cell 
lymphomas by injection of an anti-T cell mAb (17), soon 
followed by the anti-idiotype mAb treatment of B cell 
lymphoma by Levy’s group (18).1 of 9
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localization of the 131I-labeled mAb CO17-1A, in collaboration 
with Hilary Koprowski and Jean-François Chatal (19). There 
were definite positive tumor uptakes of radioactivity, but the 
tumor localization was less contrasted than with our anti-CEA 
mAbs. Interestingly, mAb CO17-1A was the same mAb that was 
later injected in large amounts without labeling by Koprowski’s 
group for the treatment of gastrointestinal carcinomas (20), and 
later by Gert Riethmüller for adjuvant treatment of Dukes C 
carcinoma patients, in order to prevent relapse or metastases by 
elimination of undetectable residual disease (21).
Lloyd was actively involved in the field of radiolabeled anti-
tumor antibodies through very efficient and productive 
collaborations with different scientists and clinicians (including 
Sidney Welt and Gerd Ritter from the New York LICR Branch 
and Steve Larson from the Nuclear Medicine Department of the 
Sloan-Kettering Institute, who had already performed 
pioneering radioimmunotherapy with a 131I-labeled anti-
melanoma mAb (22), as well as Andrew Scott and Anthony 
Burgess from the Melbourne LICR Branch).
Within a few years, these collaborations resulted in the 
selection of mAb A33, specific for an antigen expressed by 
malignant and normal gut epithelium, and a series of clinical 
studies of colorectal carcinoma patients for evaluation of mAb 
A33, labeled either with 131I for diagnosis and 
radioimmunotherapy (23), with 125I for Auger particle emission 
(24), or later, using the humanized huA33 mAb labeled with 124I 
for immunoPET quantitative imaging (25).
In parallel, the same groups evaluated the tumor localization 
of the anti-ganglioside GD3 mAb KM871 in melanoma patients 
(26), as well as the targeting of the mAb G250 (anti-renal cell 
carcinoma, developed by Dutch scientists from Leiden) with 
diagnostic (27) and therapeutic doses of 131I (28).
However, despite the highly contrasted tumor images 
demonstrated clinically, and the very encouraging 
radioimmunotherapy results obtained in human tumors 
xenografted in experimental animals by David Goldenberg (29) 
and by Franz Buchegger in our group (30), as well as by Sidney 
Welt in Lloyd’s group (31), the clinical radioimmunotherapy of 
solid tumors still did not produce significant satisfactory results. 
This is a personal conclusion based on our own last clinical 
experience with 131I-labeled anti-CEA F(ab’)2 fragments (32) 
and on a broad review of the literature (33). Indeed, the high 
radioresistance of solid tumors compared to the radiosensitivity 
of the bone marrow, which receives relatively high radiation 
doses from circulating radiolabeled antibody, remains a difficult 
problem to resolve, despite the use of antibody fragments with a 
short half-life in the circulation (30), or new methods of two-
step tumor targeting, developed by Jean-Marc Le Doussal and 
Jacques Barbet (34, 35).
In contrast, radioimmunotherapy of more radiosensitive 
target tumors, such as lymphomas, was more successful, as 
demonstrated by the use of 131I-labeled or 90Y-labeled anti-
CD20 mAbs in the treatment of non-Hodgkin B cell lymphomas 
(36, 37). Interestingly, it was when the doses of 131I isotopes used 
to label the B1 anti-CD20 mAb were progressively lowered and a 
good part of the anti-tumor effect was maintained (38) that the 
intrinsic therapeutic properties against lymphomas of the 
original B1 anti-CD20 mAb from Stuart Schlossman were 
discovered. This led to the selection of the anti-B020 rituximab, 
mimicking the previously used B1 mAb. Rituximab became the 
first FDA-approved mAb for treatment of patients with B cell 
lymphomas (39) and, importantly, also for the treatment of 
several forms of autoimmume disease. From this example, we 
can say that radiolabeled antibodies paved the way for successful 
tumor treatment by unlabeled mAbs (16).
Unlabeled monoclonal antibodies for cancer 
therapy
The success of rituximab should not make us forget that not all 
patients with lymphoma, even in the indolent form, respond to 
the unlabeled antibody, and that a higher percentage of patients 
respond to the different forms of radiolabeled anti-CD20 mAbs 
(36, 37). Furthermore, different positive experiences in the 
treatment of lymphomas with radiolabeled anti-CD20 mAbs, as 
well as our local observation of remissions of more than ten 
years in half of the patients with relapsed or refractory indolent 
B cell lymphoma treated with 131I-labeled antibody, speak in 
favor of maintaining the interest for this form of 
radioimmunotherapy (40).
The next unlabeled mAb which was approved by the FDA, for 
the treatment of HER2-positive breast carcinoma, was the 
humanized anti-HER2 mAb trastuzumab (41), followed by the 
chimeric anti-EGFR mAb cetuximab (42). It is important to 
note, however, that despite the widespread clinical use and 
commercial success of these mAbs, as well as of other mAbs with 
similar specificities, the unlabeled anti-solid tumor mAbs have 
almost always had to be used in conjunction with chemotherapy.
Lloyd's group was also extremely productive in the selection 
and testing of unlabeled mAbs for tumor therapy, as described 
in more detail in this issue of the journal by Gerd Ritter, his 
central collaborator in the field. I just want to underscore here 
the particular interest of Lloyd in the selection of a more tumor-
specific mAb, directed against the mutated form (delta 2-7) of 
EGFR commonly expressed in glioma. The discovery of the new 
anti-EGFR mAb 806 allowed its experimental evaluation not 
only in comparison with conventional anti-EGFR, but also in 
combination with the latter. Interestingly, the coinjection of the 
two mAbs, directed against two different epitopes of EGFR, 
enhanced the anti-tumor activity in human glioma 
subcutaneous or intracranial xenograft models (43). Similarly, 
the group of Yosef Yarden at the Weizmann Institute had 
demonstrated that coinjection of two mAbs directed against 
different epitopes of HER2 was more efficient than a single mAb 
in the treatment of HER2-positive xenografts (44). The latter 
observation may have led the way to the recent strategy of 
Genentech to treat HER2-positive early breast cancer by 
injection of two anti-HER2 mAbs, pertuzumab and 
trastuzumab, known to recognize different HER2 epitopes. The 
recently reported phase II clinical trial showed higher 
therapeutic benefit of coinjection of the two mAbs than 
injection of either mAb alone (45). 
In this context, I had the pleasure to collaborate with Christel 
Larbouret, Bruno Robert, and André Pèlegrin from Montpellier, 
who demonstrated in three different human pancreatic 
carcinoma xenograft models that the coinjection of two 
clinically approved mAbs directed against EGFR and HER2 had 
a definite synergistic therapeutic effect, despite the fact that the 
three target tumors expressed very low levels of HER2 (46, 47). 
The latter point suggests that the coinjection of anti-HER1 and 
anti-HER2 mAbs may be beneficial in treating carcinomas with 
a low surface expression of HER2, if they coexpress EGFR, 
which is relatively common. Another point of interest of this 
study is that the in vivo therapeutic synergism of the two mAbs 
was demonstrated on two human pancreatic carcinoma lines, 
MIA PaCa-2 and Capan-1, which both have a mutant KRas 
phenotype. The synergistic therapeutic effect may be due to an 2 of 9 www.cancerimmunity.org
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TR-FRET assay (48).
Furthermore, most interestingly, the synergy in anti-human 
pancreatic carcinoma BxPC-3 xenografts between the anti-
HER1 and -HER2 mAbs could be also demonstrated by 
coinjection of their F(ab’)2 fragments, clearly indicating that the 
anti-tumor effect was, at least in part, due to the direct reactivity 
of the fragments with the two types of HER receptors on the 
surface of the target cells, without the need for an Fc-dependent 
effector mechanism (47). As a confirmation of this point, the 
synergy against the human pancreatic carcinoma xenograft of 
the same F(ab’)2 fragments were reproduced in a model of 
immunodeficient SCID/Beige mice, lacking NK cells (48). In 
this context, one should acknowledge that despite the very large 
number of cancer patients who have been treated with mAbs, we 
still don’t know the exact mechanism of the therapeutic activity 
of each mAb.
The activation of complement by anti-tumor mAbs has been a 
subject of great interest for Lloyd. Indeed, the activation of the 
complement proteolytic cascade could help mAb therapy, not so 
much for its relatively weak capacity to lyse solid tumor cells in 
vivo, but for its properties to opsonize tumor cells by deposition 
of C3 component and release anaphylatoxins, such as C3a and 
C5a, resulting in increased vascular permeability and better 
penetration of antibodies at the tumor site. However, except for 
anti-lymphoma and for some anti-ganglioside mAbs, such as the 
anti-GD2 from Nai-Kong Cheung, now in a phase I trial for the 
treatment of neuroblastoma (49) and the well-known anti-GD3 
from Lloyd’s group (26), complement activation was not 
retained as a major anti-tumor effector mechanism. 
There is a consensus, based mostly on the work of Raphael 
Clynes and Jeffrey Ravetch (50), as well as on clinical 
observations of a correlation between FcRIIIA genetic 
polymorphism and response to mAb therapy (51), suggesting 
that most mAbs act by “antibody-dependent cell-mediated 
cytotoxicity” (ADCC). However, there may be exceptions to this 
general rule, as demonstrated by the successful synergistic 
treatment of a pancreatic carcinoma by two F(ab’)2 fragments 
directed against EGFR and HER2 (47). Furthermore, it is 
important to underscore that the two mAbs already approved 
for solid tumor therapy are directed against important tyrosine 
kinase receptors, while other mAbs such as CO17-1A or CHL6, 
from Hilary Koprowski and Ingegerd Hellström’s laboratory, 
respectively, directed against other types of surface antigens (20, 
52) did not induce significant tumor remissions despite repeated 
injections of up to 400 mg/m2.
Promising directions for improvement of 
monoclonal antibody therapy
This leads me to continue this introduction by presenting six 
directions that appear to me the most promising for the 
improvement and optimal use of mAbs for cancer therapy. 
These proposals do not pretend to be new; most of them were 
the subject of discussion with Lloyd and will be the topics of 
reports by specialists in this issue. The lengths of the paragraphs 
are dependent on the interest of Lloyd and ourselves on the 
different subjects.
Coinjection of different monoclonal antibodies
It appears that the coinjection of two or more mAbs directed 
against different relevant receptors or different epitopes of 
receptors, expressed on the surface of cancer cells, as mentioned 
above, may lead to synergistic anti-tumor activity. This may look 
too expensive, and the commercial companies are difficult to 
convince, but if we take the historical model of chemotherapy, it 
appears obvious that it is the combination of drugs attacking 
cancer cells by different mechanisms which led to success of 
many cancer treatment modalities.
Temporary enhancement of the tumor vasculature permeability
Improving the accessibility of antibodies and other drugs to 
cancer cells, by the induction of a temporary increase in 
permeability and blood flow in the tumor vessels, also appears to 
be an important factor in improving any form of cancer therapy, 
particularly with molecules as large as antibodies. Some results 
in this direction were obtained by our group, through the 
injection of tumor necrosis factor (TNF) (53), and by the group 
of Dario Neri, by injection of antibody fragments conjugated to 
cell-permeating HIV-1 TAT peptides (54). Furthermore, the 
group of Erkki Ruoslahti has recently published a series of 
provocative papers, suggesting that several peptides with an 
arginine at the C-terminus (CendR) can increase tumor vascular 
permeability through binding to neuropilin-1, and also improve 
tumor penetration of coinjected drugs including mAbs (55).
In this context, the use of the anti-VEGF bevacizumab for 
tumor therapy (56) appears paradoxical. How can a mAb that 
decreases tumor blood flow and neutralizes a permeability 
factor like VEGF nevertheless improve the efficacy of 
chemotherapeutic drugs, which requires the permeability of 
tumor blood vessels to reach the tumor cells? Rakesh Jain, who 
made important contributions to the demonstration that cancer 
drugs penetrate very poorly into tumors because of the excess 
interstitial fluid pressure within the tumor, made the hypothesis 
that bevacizumab and other anti-angiogenic therapies were 
active mostly by “normalizing” the tumor vessels (57). However, 
more recent clinical results, obtained in non-small cell lung 
carcinoma patients, demonstrated a rapid decrease in delivery of 
chemotherapy (using radiolabeled docetaxel) to tumors after 
bevacizumab injection (58).
Modification of the Fc structure of monoclonal antibodies 
Modifying the Fc structure of the anti-tumor mAbs, both 
through selected mutations (59) and/or alteration of their 
glycosylation (60) in order to increase the affinity of Fc for the 
activating receptors expressed by the effector cells, offers 
potential for therapeutic improvement. Despite the above-
mentioned demonstration of the direct anti-tumor growth effect 
of the F(ab’)2 fragments of anti-HER1 and -HER2 (47), the 
majority of anti-tumor mAbs are supposed to induce their anti-
tumor effect through the activation of effector cells engaged by 
their Fc receptor (50). This subject will be presented by the 
specialist in the field, Jeffrey Ravetch, in this issue’s commentary 
on optimizing antibodies.
Bispecific anti-tumor anti-effector cell antibodies
Another approach to bring effector T cells/NK cells in contact 
with target tumor cells is the use of bispecific antibodies with 
one arm directed at the tumor cells and the other at the effector 
cells. This strategy will be presented by Gert Riethmüller, who 
played a central role in bringing these types of bispecific 
antibodies to useful clinical applications (61). The question is 
why were these bispecific mAbs, described over 25 years ago in 
two Nature papers by the groups of Michael Bevan and David 
Segal (62, 63), so slow to become efficient in vivo and clinically 
useful?
We had shown that our locally produced bispecific anti-
EpCAM x anti-CD3 hybrid mAb was extremely efficient in www.cancerimmunity.org 3 of 9
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specifically after trace labeling with 125I in tumor xenografts 
(64), but its in vivo activity was not demonstrated. The groups of 
Reinder Bolhuis in Holland and of Maria Colnaghi in Italy 
conducted therapy trials in ovarian carcinoma patients by 
intraperitoneal coinjection of bispecific mAbs with activated 
lymphocytes, with very modest results (65). One possible 
explanation is that the affinity of the anti-CD3 arm of the early 
bispecific antibodies was too high, leading to an initial binding 
to the circulating T cells before they had reached the tumor, 
which would inhibit the subsequent targeting to the tumor cells. 
Indeed, Antonio Lanzavecchia’s group demonstrated that a 
lower affinity of the anti-CD3 arm of the bispecific mAb, 
induced by selected mutations, helped to avoid binding to 
effector T cells in the circulation. Binding of the T cells to the 
low-affinity anti-CD3 becomes possible only at the tumor site, 
by an avidity effect due to the presence of multiple copies of the 
bispecific antibody oligomerized at the surface of the tumor cells 
(66). Gert Riethmüller will tell us if that strategy was 
instrumental in the excellent activity of their recombinant 
single-chain bispecific antibody in vivo (61).
The beauty of this bispecific single-chain variable fragment 
(scFv) anti-CD19 x anti-CD3, called blinatumomab, produced 
by Riethmüller and the company behind him, is that it can 
induce tumor regressions in patients with non-Hodgkin 
lymphomas after injection at very low doses, in the range of less 
than 0.1 mg. This looks like a great advantage, as compared with 
the injection doses of rituximab, in the range of 50 to 100 mg, 
and suggests that the bispecific scFv induces a much more 
efficient mechanism of target cell killing by the CD3 effector 
cells than do the monospecific intact mAbs by an Fc-dependent 
ADCC mechanism. Whether these excellent results obtained 
against lymphomas can be also obtained by a similar strategy 
against well-established solid tumors, known to be resistant to 
active immunotherapy, still needs to be demonstrated.
Furthermore, the small size of the bispecific scFv, leading to a 
very short circulating half-life, and thus requiring several days of 
intravenous (i.v.) injection, still represents a problem. Maybe 
larger forms of bispecific antibodies that redirect T cells against 
tumors, such as the tribodies with one arm directed against the 
T cells and two against the tumor (67), or the so-called 
trifunctional bispecific antibodies with a functional Fc fragment 
(68), will compete with the bispecific scFv.
Antibody-mediated tumor targeting of antigenic MHC complexes
Another strategy for retargeting the T cells to the tumors 
consists in coating the tumor cells with an antigenic major 
histocompatibility complex (MHC)-viral peptide complex 
linked to an anti-tumor antibody fragment. We developed this 
strategy in collaboration with Bruno Robert from my group, as 
well as with Pedro Romero, Philippe Guillaume, Immanuel 
Luescher, and Jean-Charles Cerottini from the LICR Lausanne 
Branch, and reported it in one of the first research articles of 
Cancer Immunity (69). I take the liberty to describe this strategy 
in some detail, since it was supported by a Cancer Research 
Institute (CRI) grant, awarded through Lloyd, and we had 
several discussions about it, and also because it represents a real 
bridge between antibody- and T cell-mediated immunotherapy. 
Fab fragments from anti-CEA, -HER2, or -CD20 mAbs were 
chemically linked to recombinant HLA-A2 molecules, loaded 
with Flu matrix peptide, and coated on the target tumor cells 
expressing one or the other differentiation marker (LoVo/
CEA+, SKBR3/HER2+, and Daudi/CD20+). When anti-
influenza T cell clones were added, at effector-to-target cell 
ratios of 10 to 20, we obtained, in a 4 h 51Cr release assay, 
specific lysis (ranging from 60-90%) of the target tumor cells 
expressing the relevant marker recognized by the antibody Fab 
fragment of the conjugate, used at 10 to 100 picomolar 
concentrations. The beauty of the system is that, like the 
bispecific antibody described by Lanzavecchia, mentioned 
above, the monomeric HLA-A2 molecules in solution had a very 
low affinity for the T cell receptors (TCRs), but when the 
conjugate was oligomerized on the tumor cells through the Fab 
fragment, they induced a high avidity binding to the T cell 
receptors, resulting in activation and lysis. In brief, our 
conjugate had the capacity to replace a differentiation marker 
expressed by tumor cells and recognized by an antibody with an 
antigenic viral antigen recognized by a T cell receptor.
Interestingly, at that time, there was no publication in this 
field, except for the group of Philip Savage from Oxford, who 
used, for the same goal, a two-step tumor coating system 
involving first a biotin-labeled anti-CD20 antibody, followed by 
biotinylated HLA-A2/gag complexes, bridged by an avidin 
molecule (70).
At this point, it was not certain that this immunotherapy 
strategy would function in vivo in a syngeneic tumor system. 
Alena Donda and Valérie Cesson, in our group, gave a positive 
answer to this question. They first showed that injection of anti-
CEA-H2Kb/OVA peptide conjugate could induce specific 
growth inhibition and regression in a model of established 
syngeneic carcinoma, transfected with human CEA and grafted 
in OT-1 C57BL/6 mice expressing a transgenic anti-OVA TCR. 
The results were confirmed in a model of CEA-transgenic mice 
which received anti-OVA T cells from OT-1 mice (71).
One year later, the group of Yoram Reiter from Israel presented 
a similar strategy of antibody-mediated tumor cell-coating of 
antigenic MHC complexes, but with the use of a recombinant 
fusion protein consisting of an HLA-A2 molecule fused with an 
antigenic Epstein-Barr virus (EBV)-derived peptide and an anti-
tumor scFv. The results, which confirmed our approach with 
more modern tools, were published in a Proceedings of the 
National Academy of Sciences article communicated by Lloyd 
Old, confirming his interest in the field (72).
Our group further demonstrated in a fully immunocompetent 
murine model that a physiological immune response against 
lymphochoriomeningitis virus (LCMV) or influenza virus was 
sufficient to provoke the growth inhibition of tumor coated with 
anti-tumor-H2Kb conjugates loaded with the relevant 
immunodominant viral peptide (73).
In recent years, Alena Donda, who has now created her own 
research group with Pedro Romero at the Ludwig Cancer Center 
of Lausanne University and with whom I have the pleasure to 
collaborate, developed a novel related strategy, allowing the 
activation and recruitment at the tumor site of NKT cells, 
known to be at the junction between the innate and the adaptive 
arms of the immune response. For this purpose, she synthesized 
a recombinant, MHC-related, CD1d molecule fused to anti-
HER2 scFv fragments and showed that, when loaded with the 
CD1d ligand superagonist -galactosylceramide (-GalCer), 
this fusion protein, injected i.v., could induce a potent inhibition 
of lung metastases, produced by an i.v. injection of syngeneic 
HER2-transfected B16 melanoma cells, 2 to 7 days before 
treatment. Interestingly, it was discovered during these 
immunotherapy experiments that the -GalCer, when loaded 
on CD1d-scFv, induced a sustained NKT cell activation, while 
injection of free -GalCer induced an acute NKT cell activation, 
rapidly followed by the well-known NKT cell anergy, and in the 
present model, no anti-tumor effect (74). These new forms of 4 of 9 www.cancerimmunity.org
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adaptive anti-tumor responses, were developed with the 
scientific and financial support of Maurice Zauderer and his 
company, demonstrating the usefulness of collaboration 
between the University, the LICR, and private companies, as 
recommended, in recent years, by Lloyd.
Blocking of regulatory pathways by monoclonal antibodies
The last promising role of antibodies in improving cancer 
immunotherapy is the development of mAbs directed not 
against the tumor cells’ antigens, but against coinhibitory 
receptors expressed on effector T cells. Indeed, well-organized 
tumor tissues are part of our immunological self. Thus our 
organism has multiple mechanisms and regulatory molecules to 
avoid autoimmune reactions against our own tissues. These 
regulatory molecules unfortunately inhibit our efforts to raise an 
immune reaction against our own tumor. Therefore, in order to 
trigger weak anti-tumor T cell responses in the host or to 
reinforce our vaccination strategy against the selected tumor-
specific or differentiation antigens, aimed at rejecting our 
tumors, several mAbs have been derived to block the regulatory 
molecules that prevent tumor rejection. The first one, directed 
against the cytotoxic T lymphocyte-associated protein 4 (CTLA-
4) coinhibitory receptor expressed by activated and regulatory T 
cells was developed by James Allison (76), who, with Jedd 
Wolchok and Andrew Scott, will describe it in more detail in this 
issue’s commentary on antibodies in immunomodulation. 
Furthermore, additional coinhibitory receptors are 
overexpressed on “exhausted” lymphocytes during chronic 
inflammation, such as T cell immunoglobulin mucin 3 (Tim-3) 
and programmed cell death 1 (PD-1). These were found to be 
coexpressed in 50% of tumor-infiltrating lymphocytes, by Ana 
Anderson. Her group reported that simultaneous blockade of 
both Tim-3 and PD-1, by coinjection of two antibodies against 
Tim-3 and PD-L1, was highly effective in restoring T cell 
immunity in a model of CT26 carcinoma in BALB/c (76). One 
should mention also, that in parallel with the development of the 
above blocking antibodies against coinhibitory receptors, a 
series of agonistic antibodies directed against activating 
receptors, such as CD137, expressed on effector NK or T cells, 
are presently tested for enhancement of anti-tumor activity with 
encouraging experimental results (77, 78).
At the clinical level, ipilimumab, the fully human IgG1 form of 
anti-CTLA-4, was shown to prolong survival in a phase III trial 
of metastatic melanoma patients and thus was approved as a 
single agent for the first-line treatment of this condition (79). 
Ipilimumab was also found to enhance the CD4 and CD8 T cell 
responses against NY-ESO-1 CT antigen, in patients with 
durable objective clinical response or stable disease (80).
Finally, I would not like to end this introduction without a 
brief mention of yet another strategy, which is at the edge 
between antibody and T cell therapy, consisting in the design of 
chimeric antigen receptors (CARs). This approach was 
pioneered by Zelig Eshhar at the Weizmann Institute, who 
demonstrated the possibility to generate antigen receptor 
chimeras composed of the antigen recognition domains of an 
anti-tumor antibody, fused with the CD3 zeta chain, one of the 
signaling components of the TCR for antigen (81). Retroviral or 
lentiviral transduction of T cells with CARs confer to T cells the 
recognition capabilities of antibodies, which have the advantage 
of being MHC-independent, but are limited to the specific 
recognition of antigens expressed on the surface of tumor cells. 
CARs have been refined over the years and today are designed to 
contain the signaling modules of costimulatory receptors, such 
as those from CD137. Recent phase I clinical trials of cellular 
therapy with CAR-reprogrammed autologous T cells, expressing 
for at least six months functional CARs at high levels, have 
shown great promise. For instance, adoptive transfer of T cells 
carrying a CD19-specific CAR led to impressive complete 
responses in two out of three patients reported with treatment-
refractory chronic lymphocytic leukemia (82).
Conclusion
It is evident that monoclonal antibodies directed against 
particular receptor structures or differentiation markers 
overexpressed on tumor cells, but also present on normal cells, 
have had an enormous impact on present day cancer therapy. 
The fact that mAb therapy for solid tumors still needs to be 
given in conjunction with chemotherapy shows some of its 
limitations. In particular, it is not yet known to what extent the 
recruitment of innate immune effector cells at the tumor site, by 
the targeting of massive amounts of antibody molecules, can 
help in the induction of an active T cell response of the patient 
against his or her own tumor cells. Indeed, the development of 
an active immune response against the patient’s own tumor, 
expressing mutated antigens or CT antigens, is the ultimate goal 
of tumor immunologists like Lloyd, since it represents the best 
chance to prevent the development of relapsing tumor cells 
derived from tumor stem cells, often lacking the differentiation 
markers and/or remaining insensitive to chemotherapy.
In order to enhance an active anti-tumor response, I would 
definitely favor antibody strategies that bring effector T cells to 
the tumor site, like the bispecific anti-CD3/anti-tumor strategy 
or the tumor targeting of MHC, or MHC-related, antigenic 
complexes. The experience acquired with the tumor targeting of 
mAbs labeled with radioisotopes or fluorescent probes showed 
us that many other molecules, such as cytokines (83) or drugs 
(84)—subjects that I have not covered here—can be selectively 
delivered to tumors.
I am grateful to have belonged to this generation of scientists, 
who were guided by the support and enthusiasm of Lloyd Old, 
who had the chance to witness the first success of cancer 
immunotherapy, and who feel entitled to expect many more 
successes in this field in the near future.
Abbreviations
scFv, single-chain variable fragment; mAb, monoclonal anti-
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